Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 15/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977052 | 1.00 | ALDH1A1 (0.46) | ALDH1A1FFAR4KMT2ALMNAHPGD | |
| SCHEMBL27167262 | 0.90 | FFAR4 (0.45) | FFAR4KMT2A | |
| SCHEMBL29976773 | 0.90 | FFAR4 (0.45) | FFAR4KMT2A | |
| SCHEMBL2439273 | 0.87 | FFAR4 (0.54) | FFAR4 | |
| SCHEMBL2433617 | 0.79 | FFAR4 (0.51) | FFAR4 | |
| SCHEMBL9983560 | 0.77 | FFAR4 (0.46) | FFAR4KMT2A | |
| SCHEMBL2431745 | 0.77 | FFAR4 (0.48) | FFAR4KMT2A | |
| SCHEMBL9983860 | 0.76 | FFAR4 (0.43) | FFAR4 | |
| SCHEMBL9983702 | 0.76 | FFAR4 (0.45) | FFAR4KMT2A | |
| SCHEMBL9983434 | 0.75 | FFAR4 (0.51) | FFAR4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261414-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | AUTOBAHN THERAPEUTICS INC (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4334283-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | Autobahn Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240261414-A1 | FATTY ACID AMIDE HYDROLASE (FAAH) CLEAVABLE PRODRUGS OF BRAIN TARGETING ACTIVES AND COMBINATION WITH PERIPHERALLY RESTRICTED FAAH INHIBITORS | FAAH, FAAH2, FFAR1 | ALDH1A1 2257/4885FFAR4 16/4885KMT2A 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.